{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:10:52Z","timestamp":1771042252966,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The immune checkpoint inhibitor pembrolizumab has recently been recognized as a standard treatment regimen for patients with metastatic colorectal cancer and the microsatellite-instability-high\/mismatch repair-deficient mutation. However, its cost-effectiveness in late-line treatment remains unclear. The aim of this study was to assess the cost-effectiveness of pembrolizumab for patients with microsatellite-instability-high\/mismatch repair-deficient metastatic colorectal cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Markov decision modeling using treatment costs, disease-free survival and overall survival was performed to examine the cost-effectiveness of pembrolizumab monotherapy compared with chemotherapy, and best supportive care. The Japanese healthcare payer\u2019s perspective was adopted. The outcomes were modeled on the basis of published literature. The primary outcome was the incremental cost-effectiveness ratio between the strategies. Sensitivity analyses were performed and the effects of uncertainty on the model parameters were investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Pembrolizumab monotherapy had incremental cost-effectiveness ratios of $408204.3 per quality-adjusted life-year gained compared with best supportive care and $489123.4 per quality-adjusted life-year gained compared with chemotherapy. Given a Japanese willingness-to-pay threshold of $69560.38 per quality-adjusted life-year, the base case results suggested that pembrolizumab monotherapy was not cost-effective. The sensitivity analysis results were in line with the base case results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Pembrolizumab monotherapy is not a cost-effective option in late-line treatment for patients with metastatic colorectal cancer and microsatellite-instability-high\/mismatch repair-deficient mutation in the Japanese healthcare system. Further studies on its cost-effectiveness in first-line treatment are warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad050","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T18:31:08Z","timestamp":1685039468000},"page":"691-697","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1830-3849","authenticated-orcid":false,"given":"Kiyoaki","family":"Sugiura","sequence":"first","affiliation":[{"name":"Department of Surgery, Eiju General Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hiratsuka","sequence":"additional","affiliation":[{"name":"Department of Surgery, Eiju General Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Surgery, Eiju General Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Aiko","sequence":"additional","affiliation":[{"name":"Department of Surgery, Eiju General Hospital , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"2023080107331878300_ref1","author":"Colorectal cancer, GLOBOCAN 2020:","year":"2020"},{"key":"2023080107331878300_ref2","author":"National Cancer Center","year":"2022"},{"key":"2023080107331878300_ref3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3322\/caac.21601","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2023080107331878300_ref4","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-21-0557","article-title":"FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H\/dMMR advanced unresectable or metastatic colorectal carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023080107331878300_ref5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman","year":"2009","journal-title":"Br J Cancer"},{"key":"2023080107331878300_ref6","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2023080107331878300_ref7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2023080107331878300_ref8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023080107331878300_ref9","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2023080107331878300_ref10"},{"key":"2023080107331878300_ref11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"2023080107331878300_ref12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"2023080107331878300_ref13","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1002\/ONCO.13522","article-title":"Cost-effectiveness of pembrolizumab plus axitinib versus sunitinib as first-line therapy in advanced renal cell carcinoma in the U.S","volume":"26","author":"Ding","year":"2021","journal-title":"Oncologist"},{"key":"2023080107331878300_ref14","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdu100","article-title":"Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)","volume":"25","author":"Goldstein","year":"2014","journal-title":"Ann Oncol"},{"key":"2023080107331878300_ref15","volume-title":"National Health Insurance Drug Price Standard","author":"Iyaku-Hoho-Kenkyujo.Inc","year":"2016"},{"key":"2023080107331878300_ref16","volume-title":"Reimbursement Schedule of Social Insurance","author":"Laboratory","year":"2016"},{"key":"2023080107331878300_ref17","volume-title":"Reference of Diagnostic Procedure Combination","year":"2021"},{"key":"2023080107331878300_ref18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","article-title":"Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial","volume":"22","author":"Andre","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023080107331878300_ref19","year":"2013"},{"key":"2023080107331878300_ref20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working Group-6","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"key":"2023080107331878300_ref21","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"2023080107331878300_ref22","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2023080107331878300_ref23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12962-021-00329-w","article-title":"First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis","volume":"19","author":"Zhu","year":"2021","journal-title":"Cost Eff Resour Alloc"},{"key":"2023080107331878300_ref24","doi-asserted-by":"crossref","first-page":"802942","DOI":"10.3389\/fphar.2021.802942","article-title":"Cost-effectiveness of first-line versus second-line pembrolizumab or chemotherapy in patients with microsatellite-instability-high\/mismatch repair-deficient advanced colorectal cancer","volume":"12","author":"Chongqing","year":"2021","journal-title":"Front Pharmacol"},{"key":"2023080107331878300_ref25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/13696998.2022.2043634","article-title":"Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H\/dMMR colorectal cancer in the United States","volume":"25","author":"Aguiar-Ib\u00e1\u00f1ez","year":"2022","journal-title":"J Med Econ"},{"key":"2023080107331878300_ref26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cncr.31795","article-title":"Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"125","author":"Chu","year":"2019","journal-title":"Cancer"},{"key":"2023080107331878300_ref27","volume-title":"Guide to the Methods of Technology Appraisal: National Institute for Health and Care Excellence (NICE)","year":"2013"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/8\/691\/51010407\/hyad050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/8\/691\/51010407\/hyad050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T07:33:54Z","timestamp":1690875234000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/8\/691\/7187102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,5,31]]},"published-print":{"date-parts":[[2023,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad050","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,5,31]]}}}